Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib

Press/Media: Press / Media

PeriodDec 3 2018 → Dec 4 2018

Media coverage

17

Media coverage

  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date12/4/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletCanada NewsWire
    CountryCanada
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletCanada NewsWire
    CountryCanada
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletPR Newswire
    CountryUnited States
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletCanada NewsWire
    CountryCanada
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletPR Newswire
    CountryUnited States
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletPR Newswire
    CountryUnited States
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletMorningstar.com
    CountryUnited States
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletNasdaq
    CountryUnited States
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletIndia Pharma News
    CountryIndia
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletTickerTech.com
    CountryUnited States
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletSpoke.com
    CountryUnited States
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletStockwatch
    CountryCanada
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletBioSpace
    CountryUnited States
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletPharmiWeb
    CountryUnited Kingdom
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletCanadian Life Sciences Database
    CountrySwitzerland
    Date12/3/18
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
    Media name/outletCentral Charts
    CountryFrance
    Date12/3/18
    PersonsRuben Mesa